This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.
nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
The National Institute for Health and Care Excellence (NICE) has recommended the use of Lenvima (lenvatinib) after manufacturer Eisai was able to supply new data on its use. ... that NICE is finally recommending the use of lenvatinib so that patients
Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
The company "would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients, however so far an unacceptable process has again
The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC) after an accelerated assessment. ... We remain committed to exploring the potential of lenvatinib for people with cancer, their
More from news
Approximately 2 fully matching, plus 14 partially matching documents found.
The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...